Primary Hyperoxaluria Type 1 (PH1)
European Society for Paediatric Urology (ESPU) 2025
Congress Details
3-6 September 2025 | AUSTRIA
Vienna, Austria
The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
Congress Materials
Presentation Type
Location
Title
Associated Materials
Primary Hyperoxaluria Type 1 (PH1)
American Society of Nephrology (ASN) 2025
Primary Hyperoxaluria Type 1 (PH1)
European Society for Paediatric Nephrology (ESPN) 2025
Primary Hyperoxaluria Type 1 (PH1)
International Paediatric Transplant Association (IPTA) 2025
Primary Hyperoxaluria Type 1 (PH1)
European Renal Association (ERA) 2025
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial
American Journal of Kidney Diseases
Primary Hyperoxaluria Type 1 (PH1)
